MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-14-2026
ICON Public Limited Company Interest Expense 2011-2026 | ICLR
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense ICON Public Limited Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 337 M | 230 M | 182 M | 13 M | 13.3 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 337 M | 13 M | 155 M |
Quarterly Interest Expense ICON Public Limited Company
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 44.4 M | - | - | - | 2.73 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 44.4 M | 2.73 M | 23.6 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Biomerica
BMRA
|
367 | $ 2.13 | - | $ 4.89 M |  USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 74.43 | -1.72 % | $ 5.02 B | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 158.47 | 0.24 % | $ 7.85 B | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 165.48 | -0.92 % | $ 28.4 B | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 457.54 | 0.13 % | $ 13.2 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
5.9 M | $ 1.21 | -17.14 % | $ 6.59 M | USA |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 243.86 | 0.28 % | $ 25.6 B |  Schweiz |
 |
Interpace Biosciences
IDXG
|
-394 K | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 571.85 | -1.15 % | $ 46 B | USA |
 |
Illumina
ILMN
|
-292 M | $ 125.07 | 1.03 % | $ 19.9 B | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.68 | 0.54 % | $ 433 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 83.91 | -1.17 % | $ 10.5 B | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
National Research Corporation
NRC
|
-95 K | $ 17.51 | - | $ 392 M | USA |
 |
Pacific Biosciences of California
PACB
|
14.8 M | $ 1.36 | -2.52 % | $ 408 M | USA |
 |
Celcuity
CELC
|
2.11 M | $ 101.4 | -5.01 % | $ 4 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 263.49 | -0.37 % | $ 21.9 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Precipio
PRPO
|
-1 K | $ 26.85 | -0.3 % | $ 34.8 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 3.41 | -2.16 % | $ 1.83 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 7.93 | -2.1 % | $ 1.02 B | USA |
 |
Personalis
PSNL
|
24 K | $ 7.52 | -1.18 % | $ 446 M | USA |
 |
Natera
NTRA
|
9.32 M | $ 194.93 | -2.58 % | $ 19.2 B | USA |
 |
RadNet
RDNT
|
32.1 M | $ 59.45 | -3.72 % | $ 4.47 B | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 17.37 | -1.08 % | $ 926 M | USA |
 |
OPKO Health
OPK
|
207 M | $ 1.14 | -1.3 % | $ 791 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 25.36 | -1.51 % | $ 704 M | USA |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.71 | 1.36 % | $ 280 M | USA |
 |
Sotera Health Company
SHC
|
8.55 M | $ 13.8 | -0.61 % | $ 3.92 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 195.47 | -0.08 % | $ 21.7 B | USA |
 |
DarioHealth Corp.
DRIO
|
-1.93 M | $ 7.37 | -1.73 % | $ 29.4 M | Israel |
 |
DexCom
DXCM
|
177 M | $ 66.5 | 0.85 % | $ 25.9 B | USA |